Search research articles
Contact Us
Filters
Showing results (61-70 of 196) with videos related to
Page
of 20
Sort By:
Health Affairs (Project Hope)
|
October 6, 2025
Medicaid Expansion Boosted Specialty Treatment Episodes For Substance Use Disorder In Expansion States, 2010-22
Johanna Catherine Maclean, Skyler Hulser, Bradley D Stein, et al.
American Journal of Preventive Medicine
|
March 22, 2021
COVID-19 Cases Among Employees of U.S. Federal and State Prisons
Julie A Ward, Kalind Parish, Grace DiLaura, et al.
Substance Abuse
|
April 2, 2021
It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver
Brendan Saloner, Barbara Andraka Christou, Adam J Gordon, et al.
JAMA Network Open
|
July 9, 2026
Xylazine-Fentanyl Positivity and Concentration in Urine Drug Tests
Olivia K Sugarman, Charles Marks, Penn Whitley, et al.
Medical Care
|
January 11, 2023
Discontinuation of Buprenorphine Treatment for Opioid Use Disorder During the Coronavirus Disease-2019 Pandemic: A Multilevel Framework
Brendan Saloner, Hsien-Yen Chang, G Caleb Alexander, et al.
Journal of Addiction Medicine
|
August 16, 2024
Medications for Opioid Use Disorder After Entering Residential Treatment: Evidence From Louisiana Medicaid
Wenshu Li, Matthew Eisenberg, Minna Song, et al.
Medical Care
|
November 15, 2017
Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment
Marcus A Bachhuber, Pooja K Mehta, Laura J Faherty, et al.
JAMA Internal Medicine
|
August 27, 2014
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010
Marcus A Bachhuber, Brendan Saloner, Chinazo O Cunningham, et al.
JAMA Health Forum
|
August 17, 2022
Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic
Alyssa Shell Tilhou, Laura Dague, Brendan Saloner, et al.
Substance Abuse
|
September 7, 2023
Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act
Brendan Saloner, Barbara Andraka-Christou, Bradley D Stein, et al.
Page
of 20
Search research articles
Search
Showing results (61-70 of 196) with videos related to
Sort By:
Page
of 20
Health Affairs (Project Hope)
|
October 6, 2025
Medicaid Expansion Boosted Specialty Treatment Episodes For Substance Use Disorder In Expansion States, 2010-22
Johanna Catherine Maclean, Skyler Hulser, Bradley D Stein, et al.
American Journal of Preventive Medicine
|
March 22, 2021
COVID-19 Cases Among Employees of U.S. Federal and State Prisons
Julie A Ward, Kalind Parish, Grace DiLaura, et al.
Substance Abuse
|
April 2, 2021
It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver
Brendan Saloner, Barbara Andraka Christou, Adam J Gordon, et al.
JAMA Network Open
|
July 9, 2026
Xylazine-Fentanyl Positivity and Concentration in Urine Drug Tests
Olivia K Sugarman, Charles Marks, Penn Whitley, et al.
Medical Care
|
January 11, 2023
Discontinuation of Buprenorphine Treatment for Opioid Use Disorder During the Coronavirus Disease-2019 Pandemic: A Multilevel Framework
Brendan Saloner, Hsien-Yen Chang, G Caleb Alexander, et al.
Journal of Addiction Medicine
|
August 16, 2024
Medications for Opioid Use Disorder After Entering Residential Treatment: Evidence From Louisiana Medicaid
Wenshu Li, Matthew Eisenberg, Minna Song, et al.
Medical Care
|
November 15, 2017
Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment
Marcus A Bachhuber, Pooja K Mehta, Laura J Faherty, et al.
JAMA Internal Medicine
|
August 27, 2014
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010
Marcus A Bachhuber, Brendan Saloner, Chinazo O Cunningham, et al.
JAMA Health Forum
|
August 17, 2022
Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic
Alyssa Shell Tilhou, Laura Dague, Brendan Saloner, et al.
Substance Abuse
|
September 7, 2023
Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act
Brendan Saloner, Barbara Andraka-Christou, Bradley D Stein, et al.
Page
of 20